title: Consolidation chemotherapy prior to hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission.
abstract: Whether patients with acute myeloid leukemia (AML) should receive routine consolidation chemotherapy prior to transplant remains a significant question. Consolidation therapy may be advisable in the face of transplant delays, such as donor identification, insurance clearance, or transplant center scheduling, to prevent relapse prior to transplant. However, in cases where physicians have a choice, the question of the value of consolidation chemotherapy continues to be debated. This paper reviews the value of consolidation therapy in 4 different transplant settings.
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Division of Medical Oncology, University of Washington School of Medicine, 1100 Fairview Avenue North, D5-310, PO Box 19024, Seattle, WA 98109-1024, USA. Electronic address: fappelba@fhcrc.org.
authors.forename: Frederick R
authors.initials: FR
authors.lastname: Appelbaum
mesh_terms: D000328:Adult; D064591:Allografts; D060830:Consolidation Chemotherapy / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*
keywords: Acute myeloid leukemia, AML; Allogeneic; Autologous; Consolidation; Hematopoietic cell transplantation, HCT; Minimal residual disease, MRD; Myeloablative; Reduced intensity conditioning, RIC